The NCCN Guidelines Version 1.2022 Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma (WM/LPL) were updated to include zanubrutinib as a preferred regimen for the primary therapy of WM/LPL along with bendamustine/rituximab, bortezomib/dexamethasone/rituximab, ibrutinib ± rituximab, and rituximab/cyclophosphamide/dexamethasone. Preferred interventions are based on superior efficacy, safety, and evidence.

To read the full article, please click the link below:

https://www.ajmc.com/view/nccn-guidelines-add-zanubrutinib-as-preferred-therapy-for-waldenstr-m-macroglobulinemia

To view the publication (Blood. 2020;136:2038-2050. doi:10.1182/blood.2020006844) please click the link below:

https://ashpublications.org/blood/article/136/18/2038/461625/A-randomized-phase-3-trial-of-zanubrutinib-vs